Meeting Abstract

ASH Highlights and Commentary: Multiple Myeloma

Kathryn T. Maples, PharmD, BCOP

Emory University, Atlanta, Georgia


J Adv Pract Oncol 2022;13(suppl 2):7-13 | https://doi.org/10.6004/jadpro.2022.13.2.10 | © 2022 Harborside™


  

ABSTRACT

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.

Kathryn T. Maples, PharmD, BCOP, of Emory University, evaluates data on antibody therapy, which has become a critical component in the treatment of multiple myeloma. Dr. Maples reviews outcomes of multiple myeloma patients after progressing on a bispecific antibody and the efficacy and safety profiles of two BCMA- and CD3-targeting bispecific antibodies, elranatamab and teclistamab.

On the JADPRO website, you’ll find several short videos on these important abstracts that the faculty members filmed on site. Visit advancedpractitioner.com/highlights to continue the experience!




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.